Cancer immunotherapies that block two different checkpoints on T cells launch immune attacks on cancer by expanding distinct types of T cell that infiltrate tumors, researchers from The University of Texas MD Anderson Cancer Center report in the journal Cell.
“The mechanisms these two therapies use mostly do not overlap, which provides a reason why combining them works better than either alone,” said Jim Allison, Ph.D., chair and...
The University of Texas MD Anderson Cancer Center again has ranked No. 1 for cancer care by U.S. News & World Report’s annual “Best Hospitals...
For patients with advanced, inoperable stage 3 lung cancer, concurrent chemotherapy and the specialized radiation treatment, proton therapy...
Immune cells with a general knack for recognizing and killing many types of infected or abnormal cells also can be engineered to hunt down cells with specific targets on them to treat cancer, researchers at The University of Texas MD Anderson Cancer Center report in the journal Leukemia.
The team’s preclinical research shows that natural killer cells derived from donated umbilical cords can be modified to seek and destroy some...
The treatment of osteosarcoma, the most common tumor of bone, is challenging. A study led by The University of Texas MD Anderson Cancer Center...
Joint Statement from Dr. Joseph M. Herman, Clinical Research Director, Department of Radiation Oncology, The University of Texas MD Anderson...
The University of Texas MD Anderson Cancer Center today announced a new leadership structure designed to enhance teamwork and collaborative...
Two challenges in treating patients with estrogen-positive breast cancer (ER+) have been an inability to predict who will respond to standard...
Just as he has changed the lives of people suffering from a devastating genetic disease, molecular endocrinologist John J. Kopchick, Ph.D....
The University of Texas MD Anderson Cancer Center plans its 19th annual Making Cancer History® seminar in Aspen, free and open to the public...